Randomized (n = 697)

NGX-4010 (n = 482)

- 60 minutes (n = 243)
  - Completed (n = 223)
  - Early termination (n = 20)
    - Adverse event: 3
    - Unsatisfactory therapeutic response: 1
    - Non-compliance: 1
    - Death: 2
    - Lost to follow-up: 6
    - Other: 7

- 30 minutes (n = 239)
  - Completed (n = 221)
  - Early termination (n = 18)
    - Adverse event: 0
    - Unsatisfactory therapeutic response: 0
    - Non-compliance: 1
    - Death: 0
    - Lost to follow-up: 9
    - Other: 8

Control (n = 215)

- 60 minutes* (n = 115)
  - Completed (n = 105)
  - Early termination (n = 10)
    - Adverse event: 1
    - Unsatisfactory therapeutic response: 0
    - Non-compliance: 1
    - Death: 1
    - Lost to follow-up: 0
    - Other: 4

- 30 minutes* (n = 100)
  - Completed (n = 92)
  - Early termination (n = 8)
    - Adverse event: 1
    - Unsatisfactory therapeutic response: 1
    - Non-compliance: 0
    - Death: 0
    - Lost to follow-up: 4
    - Other: 2

Disposition during 12-week study period